This activity is provided by the American Society of Hematology in collaboration with The France Foundation.

Gareth J. Morgan, MD
NYU Lagone Health
New York, New York

Sikander Ailawadhi, MD
Mayo Clinic
Jacksonville, Florida

Martha Mims, MD, PhD
Baylor College of Medicine
Houston, Texas

Ajay Nooka, MD
Emory University School of Medicine
Atlanta, Georgia

Saad Usmani, MD, MBBS
Memorial Sloan Kettering Cancer Center
New York, New York

TARGET AUDIENCE
This activity is intended for hematologists, oncologists, and other healthcare team members involved in the treatment of patients with multiple myeloma.

STATEMENT OF NEED
There are some fundamental biological/genetic differences observed in multiple myeloma (MM) in African Americans. Onset tends to be earlier and African Americans have higher rates of pre-MM monoclonal gammopathy of undetermined significance (MGUS). Strikingly, if African American MM patients are afforded the same medical care as white patients, they fare as well or better. Genetic and biologic differences cannot account for disparities in overall survival (OS), leading one recent review to conclude that “innovative and multidisciplinary approaches are urgently needed to enhance our understanding of disparities that exist at each stage of the MM disease continuum and facilitate their elimination.” For clinicians to address and ameliorate racial disparities in the management of MM, they must first be aware of the disparities—from overt to subtle, clinician-level to systemic—that exist.

Upon completion of the activity, participants should be able to:

• Discuss health disparities in the treatment of multiple myeloma in African American patients
• Explain the need for culturally sensitive communication and shared decision-making strategies when discussing disease and treatment information
• Review current and emerging treatment options for multiple myeloma
• Select appropriate therapy based on evidence-based guidance and individual patient characteristics and needs
• Identify comorbidities that are particularly prevalent in African American patients, drug-drug interactions, dosing considerations, and treatment side effects

DISCLOSURE POLICY
The France Foundation participated in the development of this activity in collaboration with The American Society of Hematology. In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society of Hematology (ASH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at TFF who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, and other members at ASH who control content have no relevant financial relationships to disclose.

Faculty Disclosures-Content Creators
The faculty listed below report that they have no relevant financial relationships to disclose:

• Dr. Gareth Morgan

The following faculty report that they have relevant financial relationships to disclose:

• Dr. Ailawadhi does non-CE consulting for Amgen, AstraZeneca, Beignen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, and Takeda
• Dr. Mims receives clinical trial support from Aveo, Celgene, DeNova, Incyte, and Pfizer. She holds stock in Amgen and Biogen.
• Dr. Nooka participated in advisory boards for Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Karyopharm, Oncopeptides, Sanofi, and Takeda
• Dr. Usmani serves as a consultant for Amgen, Bristol Myers Squibb, Celgene, EdoPharma, GlaxoSmithKline, Janssen, Merck, Sanofi, SkylineDx, and Takeda. He serves on the speakers bureau for Amgen, Celgene, Janssen, Sanofi, and Takeda. Dr. Usmani also does contract research for Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda.

TFF and ASH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an educational grant from Bristol Myers Squibb.

ACCREDITATION STATEMENT
The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians
ASH designates each enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ per activity. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Certificate of Participation
Non-physicians may claim a Certificate of Participation documenting their participation in the accredited CME activity.

The France Foundation and the American Society of Hematology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASH, and the commercial supporter(s) assume no liability for the information herein.

Copyright © 2021 The France Foundation and The American Society of Hematology. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at https://www.francefoundation.com/privacy.